OCUP vs. UNCY, LEXX, XLO, APLM, PMN, CARA, IMRX, BOLT, MRKR, and RMTI
Should you be buying Ocuphire Pharma stock or one of its competitors? The main competitors of Ocuphire Pharma include Unicycive Therapeutics (UNCY), Lexaria Bioscience (LEXX), Xilio Therapeutics (XLO), Apollomics (APLM), ProMIS Neurosciences (PMN), Cara Therapeutics (CARA), Immuneering (IMRX), Bolt Biotherapeutics (BOLT), Marker Therapeutics (MRKR), and Rockwell Medical (RMTI). These companies are all part of the "pharmaceutical preparations" industry.
Ocuphire Pharma (NASDAQ:OCUP) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk, community ranking and dividends.
Ocuphire Pharma has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 2.72, indicating that its share price is 172% more volatile than the S&P 500.
Ocuphire Pharma received 13 more outperform votes than Unicycive Therapeutics when rated by MarketBeat users. Likewise, 65.96% of users gave Ocuphire Pharma an outperform vote while only 64.29% of users gave Unicycive Therapeutics an outperform vote.
Unicycive Therapeutics has a net margin of 0.00% compared to Ocuphire Pharma's net margin of -52.42%. Unicycive Therapeutics' return on equity of 0.00% beat Ocuphire Pharma's return on equity.
15.0% of Ocuphire Pharma shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 8.7% of Ocuphire Pharma shares are held by insiders. Comparatively, 42.0% of Unicycive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Ocuphire Pharma had 3 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 3 mentions for Ocuphire Pharma and 0 mentions for Unicycive Therapeutics. Ocuphire Pharma's average media sentiment score of 0.22 beat Unicycive Therapeutics' score of 0.00 indicating that Ocuphire Pharma is being referred to more favorably in the media.
Ocuphire Pharma currently has a consensus target price of $19.00, indicating a potential upside of 938.25%. Unicycive Therapeutics has a consensus target price of $5.30, indicating a potential upside of 375.34%. Given Ocuphire Pharma's higher possible upside, equities analysts clearly believe Ocuphire Pharma is more favorable than Unicycive Therapeutics.
Ocuphire Pharma has higher revenue and earnings than Unicycive Therapeutics. Ocuphire Pharma is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Ocuphire Pharma beats Unicycive Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Ocuphire Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCUP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OCUP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ocuphire Pharma Competitors List
Related Companies and Tools
